Azoulay-Dupuis E, Mohler J,
Bédos J, Schmitt-Hoffmann A,
Shapiro S. Efficacy of BAL5788, a
Prodrug of Cephalosporin BAL9141, in
a Mouse Model of Acute Pneumococcal
Pneumonia. 42nd ICAAC 2002. Poster
F-335.
Bernabeu A, Shapiro S, Villalain
J. A MAS-NMR study of the location of
(+)-totarol, a diterpenoid bioactive
molecule, in phospholipid model
membranes. Chemistry and Physics of
Lipids 2002; 119(1-2):
33–39.
Dreier J, Breitmaier EB, Gocke E,
Apfel CM, Page MGP. Direct influence
of S9 liver homogenate on
fluorescence signals: impact on
practical applications in a bacterial
genotoxicity assay. Mutation Research
2002; 513(1-2):
169–182.
Entenza JM, Hohl P, Heinze-Krauss
I, Glauser MP, Moreillon P. BAL9141,
a novel extended-spectrum
cephalosporin active against
methicillin-resistant Staphylococcus
aureus in treatment of experimental
endocarditis. Antimicrob Ag Chemother
2002; 46: 171–177.
Guo GJ, Nahong Q, Page MGP.
Universal restriction site-free
cloning method using chimeric
primers. BioTechniques 2002; 32(3):
516–520.
Hujer AM, Page MGP, Helfand MS,
Yeiser B, Bonomo RA. Development of a
sensitive and specific enzyme-linked
immunosorbent assay for detecting and
quantifying CMY-2 and SHV
beta-lactamases. Journal of Clinical
Microbiology 2002; 40(6):
1947–1957.
Jones RN, Deshpande LM, Mutnick
AH, Biedenbach DJ. In vitro
evaluation of BAL9141, a novel
parenteral cephalosporin active
against oxacillin-resistant
staphylococci. J of Antimicrob
Chemother, 2002; 50:
915–932.
Mouton JW, Schmitt-Hoffmann A,
Shapiro S, Nashed N, Punt NC. Monte
Carlo Predictions of dosage regimens
for BAL5788, a new broad-spectrum
cephalosporin active against MRSA.
42nd ICAAC 2002. Poster
F-336.
Ohwada J, Tsukazaki M, Hayase T,
et al. RO009855 a Novel Water Soluble
Azole Prodrug for Parenteral and Oral
Administration (I) Design, Synthesis,
Physicochemical Properties and
Bioconversion. 42nd ICAAC 2002.
Poster: F-820.
Schmitt-Hoffmann A, Kovacs P,
Roos B, et al. Preliminary
Pharmacokinetics and Safety of
BAL9141 after Single Ascending Dose
Infusions of BAL5788 in Volunteers.
42nd ICAAC 2002. Poster
F-337.
Shapiro S, Giertsen E, Guggenheim
B. An in vitro Oral Biofilm Model for
Comparing the Efficacy of
Antimicrobial Mouthrinses. Caries
Research 2002; 36(2):
93–100.
Wagner C, De Saizieu A, Schonfeld
H-J, Kamber M, Lange R, Thompson CJ,
Page MG. Genetic analysis and
functional characterization of the
Streptococcus pneumoniae vic operon.
Infection and Immunity 2002; 70(11):
6121–6128.
Wootton M, Bowker KE, Holt HA,
MacGowan AP. BAL9141, a new broad
spectrum pyrrolidinone cephalosporin:
activity against clinically
significant anaerobes in comparison
with ten other antimicrobials. J
Antimicrob Chemother 2002; 49:
535–539.
Yamazaki T, Tsukaguchi T, Ono Y,
et al. RO0098557, a Novel Water
Soluble Azole Prodrug for Parenteral
and Oral Administration (II) Prodrug
Principle and Broad Spectrum
Antifungal. 42nd ICAAC 2002. Poster
F-821.
Zbinden R, Punter V, von
Graevenitz A. In vitro activities of
BAL9141, a novel broad-spectrum
pyrrolidinone cephalosporin, against
Gram-negative nonfermenters.
Antimicrob Ag Chemother 2002; 46:
871–874.